Stocks · News reference
Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a clinical-stage biotechnology company pioneering the development of systemically delivered, targeted genetic medicines, presented on
Reference details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(2.94) per share. This is a 47.74 percent decrease over losses of $(1.99) per share from the same period last year.
Read original at benzingaCrown Holdings Inc (CCK) stock gained 16.4% in pre-market trading after reporting strong Q2 results and raising its FY26 EPS guidance. Other gaining stocks include SLGB, HIHO, WNW, CHNR, RDGT, ULBI, GLMD, SMTK, and PRTA while LBGJ is down 45.1%.
Read original at benzingaCalidi Biotherapeutics announced a 1-for-16 reverse stock split effective July 31, 2026, approved by stockholders on June 12, 2026. The company aims to optimize market dynamics and broaden investor appeal. Every 16 pre-split shares will consolidate into one share, with fractional shares rounded up to the nearest whole share.
Read original at globenewswire-inc